Followers | 196 |
Posts | 24343 |
Boards Moderated | 0 |
Alias Born | 04/03/2010 |
Monday, February 19, 2018 5:26:39 PM
You have two things that mitigate against it being likely:
1. They lost on a motion to dismiss, after amending their claim, and did not refile... on a case for which their theory was the key presumption for making a securities law violation. A motion to dismiss generally presumes a plaintiff's case is true as it has been pleaded, but you need to have just a small smidgen of some possible evidence that your claim is vaguely real. They could not meet the LOWEST standard in a federal court to proceed. We all know from the multitude of baseless claims in courts, that to not meet such a low standard, and not file again, means they failed completely to make their case even to the slightest degree when subjected to an actual standard of evidence, though it is the lowest required in a court of law. They can only meet the level of evidence required to create false controversy on bulletin boards, blogs and in rhetorical hit pieces that are examples of very poor "journalism" and that show a failure to even comprehend the basic science involved.
2. We have at least one known example, possibly others, where the FDA approved a patient's compassionate use of DCVax-L in 2016, and no evidence of a requirement of disclosure of a failure or a futility determination. That seems very unlikely given the facts that shorts allege unless the facts they allege are not consistent with the reality.
There are many other bits, but I look at these details and each time a short makes an argument, can only roll my eyes at their determination to keep raising the same points over and over again, despite the above, particularly the first item, but especially now, the 2nd detail. In the fact-based world I inhabit, the FDA is a responsible agency that makes fact-based decisions patients and their doctors know the relevant risks, and does not allow people to be ripped off if a trial has failed or been found to be futile - and even if there were some profound ambiguity, full disclosure would need to be provided. I don't see any patient proceeding based upon the facts alleged by shorts or getting approved.
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM